Zacks Small Cap Issues Optimistic Estimate for TNXP Earnings

Key Points

• Zacks Small Cap has increased its Q2 2025 earnings per share estimate for Tonix Pharmaceuticals to ($3.51), significantly improving from the previous estimate of ($10.73).
• Tonix Pharmaceuticals reported earnings of (2.84) per share for its last quarter, surpassing analysts' expectations of (3.23) by $0.39.
• Insider activity includes CEO Seth Lederman purchasing 4,000 shares at an average cost of $21.55 per share, marking an 80,000% increase in his position.

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) - Equities research analysts at Zacks Small Cap upped their Q2 2025 earnings per share (EPS) estimates for Tonix Pharmaceuticals in a note issued to investors on Tuesday, July 29th. Zacks Small Cap analyst D. Bautz now anticipates that the company will post earnings per share of ($3.51) for the quarter, up from their previous forecast of ($10.73). The consensus estimate for Tonix Pharmaceuticals' current full-year earnings is ($1,762.50) per share. Zacks Small Cap also issued estimates for Tonix Pharmaceuticals' Q3 2025 earnings at ($3.24) EPS, Q4 2025 earnings at ($3.91) EPS and FY2025 earnings at ($13.68) EPS.

TNXP has been the topic of a number of other reports. Alliance Global Partners reaffirmed a "buy" rating on shares of Tonix Pharmaceuticals in a research note on Tuesday, June 3rd. Wall Street Zen upgraded Tonix Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday, June 7th.

Tonix Pharmaceuticals Price Performance

Shares of TNXP stock traded up $5.88 on Thursday, reaching $44.89. 1,173,226 shares of the company were exchanged, compared to its average volume of 1,308,990. The company has a 50-day moving average of $38.84 and a 200-day moving average of $26.01. The company has a market cap of $330.35 million, a price-to-earnings ratio of -0.02 and a beta of 1.70. Tonix Pharmaceuticals has a one year low of $6.76 and a one year high of $130.00.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported ($2.84) EPS for the quarter, topping the consensus estimate of ($3.23) by $0.39. Tonix Pharmaceuticals had a negative net margin of 1,313.87% and a negative return on equity of 120.96%. The company had revenue of $2.43 million during the quarter, compared to the consensus estimate of $2.55 million.

Insider Activity

In other Tonix Pharmaceuticals news, CEO Seth Lederman bought 4,000 shares of the firm's stock in a transaction dated Thursday, May 15th. The stock was bought at an average cost of $21.55 per share, with a total value of $86,200.00. Following the completion of the transaction, the chief executive officer directly owned 4,005 shares in the company, valued at approximately $86,307.75. The trade was a 80,000.00% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. 0.03% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Tonix Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in TNXP. Rhumbline Advisers bought a new stake in Tonix Pharmaceuticals during the 1st quarter worth approximately $244,000. Royal Bank of Canada bought a new stake in Tonix Pharmaceuticals during the first quarter worth $610,000. Caitong International Asset Management Co. Ltd bought a new stake in Tonix Pharmaceuticals during the first quarter worth $405,000. IFP Advisors Inc purchased a new stake in Tonix Pharmaceuticals in the 1st quarter valued at $179,000. Finally, Two Sigma Investments LP bought a new position in Tonix Pharmaceuticals during the 4th quarter valued at $66,000. Institutional investors and hedge funds own 82.26% of the company's stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.